abt-751

ABT-751 is an orally bioavailable small molecule antimitotic sulfonamide that binds to the colchicine-binding site on beta-tubulin, inhibiting microtubule polymerization and thereby preventing tumor cell replication. It has demonstrated antitumor activity in preclinical models, including those resistant to conventional chemotherapies, and exhibits antivascular properties by disrupting microtubules in vascular endothelial cells. ABT‑751 was developed as a potential alternative to taxane-based therapies and has been investigated for various cancers, including non-small cell lung cancer, breast cancer, colorectal cancer, renal cancer, liver cancer, melanoma, and pediatric neuroblastoma.

Other names

N-[2-(4-hydroxyanilino)-3-pyridinyl]-4-methoxybenzenesulfonamideN-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamideN-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide